- Home
- Products
- Customized ADCs
- EFNA4
- Anti-EFNA4 (clone huE47)-AcBut-CM ADC
Anti-EFNA4 (clone huE47)-AcBut-CM ADC (CAT#: ADC-W-019)
This ADC product is comprised of an anti-EFNA4 monoclonal antibody (clone huE47)) conjugated via an AcBut linker to CM. The CM is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis.
- Product Information
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Antibody clone #
- huE47
- Name
- EFNA4
- Alternative Names
- ephrin-A4; EFL4; EPLG4; LERK4; LERK-4; ligand of eph-related kinase 4; eph-related receptor tyrosine kinase ligand 4;
- Target Entrez Gene ID
- 1945
- Target UniProt ID
- P52798
- Overview
- This gene encodes a member of the ephrin (EPH) family. The ephrins and EPH-related receptors comprise the largest subfamily of receptor protein-tyrosine kinases and have been implicated in mediating developmental events, especially in the nervous system and in erythropoiesis. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. This gene encodes an EFNA class ephrin. Three transcript variants that encode distinct proteins have been identified.
- Overview
- Anti-EFNA4-antibody, clone # huE47
- Clone #
- huE47
- Species Reactivity
- Human
- Name
- AcBut [-(4' acetyl phenoxy) butanoic acid]
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Name
- CM (N-acetyl-y-calicheamicin dimethyl hydrazide)
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-EPCAM (Edrecolomab)-MC-MMAF ADC (CAT#: ADC-W-1096)
- Anti-S1P (Sonepcizumab)-MC-MMAF ADC (CAT#: ADC-W-2434)
- Anti-NGcGM3 (Racotumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2269)
- Anti-CEACAM8 (Besilesomab)-SPDB-DM4 ADC (CAT#: ADC-W-2205)
- Anti-MUC1 (huC242)-SMCC-[3H]DM1 ADC (CAT#: ADC-W-234)
- Anti-ERBB2 (trastuzumab)-Aminocaproyl-MMAF ADC (CAT#: ADC-W-635)
- Anti-DLL4 -MC-MMAF ADC (CAT#: ADC-W-1024)
- Anti-IFNA1 (Faralimomab)-SMCC-DM1 ADC (CAT#: ADC-W-1220)
- Anti-ITGA2B (Abciximab)-SMCC-DM1 ADC (CAT#: ADC-W-1460)
- Anti-IL2RA (Basiliximab)-MC-MMAF ADC (CAT#: ADC-W-1366)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-019. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-018 | Anti-EFNA4 (clone huE22)-AcBut-CM ADC | AcBut [-(4' acetyl phenoxy) butanoic acid] | CM (N-acetyl-y-calicheamicin dimethyl hydrazide) |
CAT# | Product Name | Linker | Payload |
ADC-W-008 | Anti-TPBG (clone A1)-AcBut-calicheamicin ADC | AcBut [-(4' acetyl phenoxy) butanoic acid] | calicheamicin |
ADC-W-332 | Anti-CD22 (clone 10F4)-AcBut-Calicheamicin ADC | AcBut [-(4' acetyl phenoxy) butanoic acid] | calicheamicin |
ADC-W-459 | Anti-FUT3 (clone hu3S193)-AcBut-CalichDMH ADC | AcBut [-(4' acetyl phenoxy) butanoic acid] | CalichDMH |
ADC-W-018 | Anti-EFNA4 (clone huE22)-AcBut-CM ADC | AcBut [-(4' acetyl phenoxy) butanoic acid] | CM (N-acetyl-y-calicheamicin dimethyl hydrazide) |
ADC-W-357 | Anti-CD33 (clone HuM195)-AcBut-Calicheamicin ADC | AcBut [-(4' acetyl phenoxy) butanoic acid] | calicheamicin |
CAT# | Product Name | Linker | Payload |
ADC-W-018 | Anti-EFNA4 (clone huE22)-AcBut-CM ADC | AcBut [-(4' acetyl phenoxy) butanoic acid] | CM (N-acetyl-y-calicheamicin dimethyl hydrazide) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.